^
Association details:
| Biomarker: | RET positive + SMARCA4 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | RET inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
1007P - Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC
Published date:
09/05/2022
Excerpt:
This multicentric retrospective study included 24 centres. Eligible pts had a RET+ aNSCLC, were treated with a RETi….KRAS G12V mutation and SMARCA4 alterations were found only in poor responders (4.5% vs 0%, p=0.2; and 25% vs 0%, p=0.04, respectively)….SMARCA4 and KRAS co-mutations may have a role in primary resistance to RETi.
